Clinical trial T1118 translocation Anti-TNF agents IL23 Kidney diseases Small molecules Cancer Thérapie ciblée IBD COLON-CANCER Colorectal cancer Therapeutics Rituximab plus chlorambucil Disease Progression Endoscopic treatment Intestinal crypts Effectiveness Heart disease risk factors Immune cells CARCINOGENESIS Patients experience Colectomy Screening Cell adhesion Patient-reported outcome Bactéries Methylation HIV Biomarker Gene expression Dysbiose Ulcerative colitis DNA methylation Epigénétiques RISK Venous thromboembolism Disease progression Neoadjuvant chemotherapy DNA METHYLATION Crohn's disease Bacteria Inflammatory Bowel Diseases Anti-TNF Upper gastrointestinal tract Monitoring Tailored therapy Eligibility Méthylation Ustekinumab Acceptability MORTALITY Consensus Maintenance therapy Stricture MICROBIOTA 18 FDG-PET/CT Cost effectiveness Rituximab Safety Gene methylation Helicobacter pylori Eradication Colon Microbiota Contraindication Disability Vedolizumab MARKER Microbiote Colorectal cancer Colibactin and lipids Alkylating agents Over 80s Biologics Original Article Clinical Crohn’s disease Epigenetics Colon cancer Tuberculosis Inflammatory bowel disease Drug Survival Résistance Immunosuppressant Fecal microbiota PCR Colonic epithelial primary cells Algorithm Clinical guidelines MALT Gènes Inflammatory bowel diseases Inhibitor IL12 Parvimonas micra Genes Resistance Dysbiosis Primary sclerosing cholangitis Surgery Inclusion